167 related articles for article (PubMed ID: 22110220)
1. ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
Yarom N; Stewart D; Avruch L; Malik R; Wells J; Jonker DJ
Anticancer Res; 2011 Nov; 31(11):3921-5. PubMed ID: 22110220
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
3. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
5. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
6. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
7. [Adrenocortical carcinoma and its treatment].
Tupikowski W; Bednarek-Tupikowska G; Florczak A
Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
[TBL] [Abstract][Full Text] [Related]
8. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
9. Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
Beom SH; Lee KW; Yang Y; Choi Y; Song KH; Kim YJ; Kim JH; Bang SM; Chung JH; Lee JS
Jpn J Clin Oncol; 2011 Nov; 41(11):1287-91. PubMed ID: 21980052
[TBL] [Abstract][Full Text] [Related]
10. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
11. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
12. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.
Michalkiewicz E; Sandrini R; Figueiredo B; Miranda EC; Caran E; Oliveira-Filho AG; Marques R; Pianovski MA; Lacerda L; Cristofani LM; Jenkins J; Rodriguez-Galindo C; Ribeiro RC
J Clin Oncol; 2004 Mar; 22(5):838-45. PubMed ID: 14990639
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic chemotherapy for adrenocortical carcinoma.
Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
[TBL] [Abstract][Full Text] [Related]
14. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical cancer treatment.
Patalano A; Brancato V; Mantero F
Horm Res; 2009 Jan; 71 Suppl 1():99-104. PubMed ID: 19153517
[TBL] [Abstract][Full Text] [Related]
16. Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
Wahab NA; Zainudin S; AbAziz A; Mustafa N; Sukor N; Kamaruddin NA
Arch Iran Med; 2016 Sep; 19(9):671-3. PubMed ID: 27631184
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
18. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.
Schwarte S; Brabant EG; Bastian L; Bruns F
Anticancer Res; 2007; 27(4A):1917-20. PubMed ID: 17649795
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of adrenocortical carcinoma.
Fassnacht M; Allolio B
Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Kelland L
Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]